Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 10;38(20):2341-2350.
doi: 10.1200/JCO.19.02896. Epub 2020 May 22.

Breast Cancer-Related Lymphedema: Risk Factors, Screening, Management, and the Impact of Locoregional Treatment

Affiliations
Review

Breast Cancer-Related Lymphedema: Risk Factors, Screening, Management, and the Impact of Locoregional Treatment

Sarah A McLaughlin et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.

Figures

FIG 1.
FIG 1.
Semiannual hazard rate for development of breast cancer–related lymphedema for the entire cohort and by axillary surgery and radiation groups. ALND, axillary lymph node dissection; RLNR, regional lymph node radiation; SLNB, sentinel lymph node biopsy. Reprinted from McDuff et al, with permission of Elsevier.
FIG 2.
FIG 2.
Histogram of baseline arm asymmetry. Magnitude of baseline asymmetry > 5% and > 10% is shaded; 28.3% and 2.9% of the study cohort have magnitude of baseline asymmetry > 5% and > 10%, respectively. Reprinted from Sun et al, by permission from Springer Nature.
FIG 3.
FIG 3.
Relative arm volume change corresponding to arm volume increase by 200 mL in the unaffected arm of 677 patients. Reprinted from Ancukiewicz et al, by permission from Springer Nature.
FIG 4.
FIG 4.
Common objective measurement tools for breast cancer–related lymphedema screening: bioimpedance spectroscopy (SOZO Bioimpedance Spectroscopy Device; ImpediMed, Carlsbad, CA). Copyright © ImpediMed Limited and ImpediMed, Perometry, Girth Measures.

References

    1. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–933. - PMC - PubMed
    1. Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455–1461. - PMC - PubMed
    1. Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): A phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297–305. - PMC - PubMed
    1. Shaitelman SF, Chiang Y-J, Griffin KD, et al. Radiation therapy targets and the risk of breast cancer-related lymphedema: A systematic review and network meta-analysis. Breast Cancer Res Treat. 2017;162:201–215. - PubMed
    1. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. JAMA. 2011;305:569–575. - PMC - PubMed

Publication types